دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Future of SARS-CoV-2 Vaccination — Lessons from Influenza
Arnold S. Monto, M.D.
doi : 10.1056/NEJMp2113403
N Engl J Med 2021; 385:1825-1827
When Women and Children Made the Policy Agenda — The Sheppard–Towner Act, 100 Years Later
Jeffrey P. Baker, M.D., Ph.D.
doi : 10.1056/NEJMp2031669
N Engl J Med 2021; 385:1827-1829
The Billboard
Rachel H. Kowalsky, M.D., M.P.H.
doi : 10.1056/NEJMp2112010
N Engl J Med 2021; 385:1829-1831
A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke
Natalie E. LeCouffe, M.D., Manon Kappelhof, M.D., Kilian M. Treurniet, M.D., Ph.D., Leon A. Rinkel, M.D., Agnetha E. Bruggeman, M.D., Olvert A. Berkhemer, M.D., Ph.D., Lennard Wolff, M.D., Henk van Voorst, M.D., Manon L. Tolhuisen, M.Sc., Diederik W.J. Dippel, M.D., Ph.D., Aad van der Lugt, M.D., Ph.D., Adriaan C.G.M. van Es, M.D., Ph.D., Jelis Boiten, M.D., Ph.D., Geert J. Lycklama à Nijeholt, M.D., Ph.D., Koos Keizer, M.D., Ph.D., Rob A.R. Gons, M.D., Ph.D., Lonneke S.F. Yo, M.D., Robert J. van Oostenbrugge, M.D., Ph.D., Wim H. van Zwam, M.D., Ph.D., Bob Roozenbeek, M.D., Ph.D., H. Bart van der Worp, M.D., Ph.D., Rob T.H. Lo, M.D., Ph.D., Ido R. van den Wijngaard, M.D., Ph.D., Inger R. de Ridder, M.D., Ph.D., Vincent Costalat, M.D., Ph.D., Caroline Arquizan, M.D., Robin Lemmens, M.D., Ph.D., Jelle Demeestere, M.D., Jeannette Hofmeijer, M.D., Ph.D., Jasper M. Martens, M.D., Wouter J. Schonewille, M.D., Ph.D., Jan-Albert Vos, M.D., Ph.D., Maarten Uyttenboogaart, M.D., Ph.D., Reinoud P.H. Bokkers, M.D., Ph.D., Julia H. van Tuijl, M.D., Ph.D., Hans Kortman, M.D., Floris H.B.M. Schreuder, M.D., Ph.D., Hieronymus D. Boogaarts, M.D., Ph.D., Karlijn F. de Laat, M.D., Ph.D., Lukas C. van Dijk, M.D., Ph.D., Heleen M. den Hertog, M.D., Ph.D., Boudewijn A.A.M. van Hasselt, M.D., Paul J.A.M. Brouwers, M.D., Ph.D., Tomas Bulut, M.D., Michel J.M. Remmers, M.D., Anouk van Norden, M.D., Farshad Imani, M.D., Anouk D. Rozeman, M.D., Ph.D., Otto E.H. Elgersma, M.D., Ph.D., Philippe Desfontaines, M.D., Denis Brisbois, M.D., Yves Samson, M.D., Frédéric Clarençon, M.D., Ph.D., G. Menno Krietemeijer, M.D., Alida A. Postma, M.D., Ph.D., Pieter-Jan van Doormaal, M.D., René van den Berg, M.D., Ph.D., Anouk van der Hoorn, M.D., Ph.D., Ludo F.M. Beenen, M.D., Ph.D., Daan Nieboer, M.Sc., Hester F. Lingsma, Ph.D., Bart J. Emmer, M.D., Ph.D., Jonathan M. Coutinho, M.D., Ph.D., Charles B.L.M. Majoie, M.D., Ph.D., and Yvo B.W.E.M. Roos, M.D., Ph.D. for the MR CLEAN–NO IV Investigators*
doi : 10.1056/NEJMoa2107727
N Engl J Med 2021; 385:1833-1844
The value of administering intravenous alteplase before endovascular treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in non-Asian populations.
Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
Marc A. Pfeffer, M.D., Ph.D., Brian Claggett, Ph.D., Eldrin F. Lewis, M.D., M.P.H., Christopher B. Granger, M.D., Lars Køber, M.D., Aldo P. Maggioni, M.D., Douglas L. Mann, M.D., John J.V. McMurray, M.D., Jean-Lucien Rouleau, M.D., Scott D. Solomon, M.D., Philippe G. Steg, M.D., Otavio Berwanger, M.D., Ph.D., Maja Cikes, M.D., Ph.D., Carmine G. De Pasquale, B.M., B.S., Ph.D., Cara East, M.D., Alberto Fernandez, M.D., Karola Jering, M.D., Ulf Landmesser, M.D., Roxana Mehran, M.D., Béla Merkely, M.D., Ph.D., Freny Vaghaiwalla Mody, M.D., Mark C. Petrie, M.D., Ivo Petrov, M.D., Ph.D., Morten Schou, M.D., Ph.D., Michele Senni, M.D., David Sim, M.B., B.S., M.Med., Peter van der Meer, M.D., Ph.D., Martin Lefkowitz, M.D., Yinong Zhou, M.D., Jianjian Gong, Ph.D., and Eugene Braunwald, M.D. for the PARADISE-MI Investigators and Committees*
doi : 10.1056/NEJMoa2104508
N Engl J Med 2021; 385:1845-1855
In patients with symptomatic heart failure, sacubitril–valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting–enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Nicoletta Colombo, M.D., Ph.D., Coraline Dubot, M.D., Domenica Lorusso, M.D., Ph.D., M. Valeria Caceres, M.D., Ph.D., Kosei Hasegawa, M.D., Ph.D., Ronnie Shapira-Frommer, M.D., Krishnansu S. Tewari, M.D., Pamela Salman, M.D., Edwin Hoyos Usta, M.D., Eduardo Yañez, M.D., Mahmut Gümü?, M.D., Mivael Olivera Hurtado de Mendoza, M.D., Vanessa Samouëlian, M.D., Ph.D., Vincent Castonguay, M.D., Alexander Arkhipov, M.D., Ph.D., Sarper Toker, M.D., M.B.A., Kan Li, Ph.D., Stephen M. Keefe, M.D., and Bradley J. Monk, M.D. for the KEYNOTE-826 Investigators*
doi : 10.1056/NEJMoa2112435
N Engl J Med 2021; 385:1856-1867
Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with or without bevacizumab.
100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report
The 100,000 Genomes Project Pilot Investigators
doi : 10.1056/NEJMoa2035790
N Engl J Med 2021; 385:1868-1880
The U.K. 100,000 Genomes Project is in the process of investigating the role of genome sequencing in patients with undiagnosed rare diseases after usual care and the alignment of this research with health care implementation in the U.K. National Health Service. Other parts of this project focus on patients with cancer and infection.
Pollution and the Heart
Sanjay Rajagopalan, M.D., and Philip J. Landrigan, M.D.
doi : 10.1056/NEJMra2030281
N Engl J Med 2021; 385:1881-1892
Yellow Sac Spider Bite
Adam S. Cifu, M.D., and Sarah L. Stein, M.D.
doi : 10.1056/NEJMicm2108561
N Engl J Med 2021; 385:1893
Ocular Findings in the Sturge–Weber Syndrome
Eduardo Roditi, M.D., and Elishai Assayag, M.D.
doi : 10.1056/NEJMicm2107640
N Engl J Med 2021; 385:e68
Case 34-2021: A 38-Year-Old Man with Altered Mental Status and New Onset of Seizures
Andrew J. Cole, M.D., Jonathan E. Slutzman, M.D., Edward T. Ryan, M.D., Michael H. Lev, M.D., and George Eng, M.D., Ph.D.
doi : 10.1056/NEJMcpc2027080
N Engl J Med 2021; 385:1894-1902
Alteplase and Thrombectomy — Not a Bridge to Dismantle
Alfonso Ciccone, M.D.
doi : 10.1056/NEJMe2112663
N Engl J Med 2021; 385:1904-1905
Drawing Boundaries around PARADISE
Lynne W. Stevenson, M.D., and Andrew P. DeFilippis, M.D.
doi : 10.1056/NEJMe2115471
N Engl J Med 2021; 385:1906-1907
Audio Interview: Covid-19 in Brazil and New Evidence for Vaccinating Younger Children
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Beatriz Grinsztejn, M.D., Ph.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2117854
N Engl J Med 2021; 385:e79
The IARC Perspective on Cervical Cancer Screening
Véronique Bouvard, Ph.D., Nicolas Wentzensen, M.D., Ph.D., Anne Mackie, M.B., B.S., Johannes Berkhof, Ph.D., Julia Brotherton, M.D., Ph.D., Paolo Giorgi-Rossi, Ph.D., Rachel Kupets, M.D., Robert Smith, Ph.D., Silvina Arrossi, Ph.D., Karima Bendahhou, M.D., M.P.H., Karen Canfell, D.Phil., F.A.H.M.S., Z. Mike Chirenje, M.D., Michael H. Chung, M.D., M.P.H., Marta del Pino, M.D., Ph.D., Silvia de Sanjosé, M.D., Ph.D., Miriam Elfström, Ph.D., Eduardo L. Franco, M.P.H., Dr.P.H., Chisato Hamashima, M.D., Dr.Med.Sc., Françoise F. Hamers, M.D., Ph.D., M.P.H., C. Simon Herrington, D.Phil., F.R.C.P., F.R.C.P.E., F.R.C.Path., Raúl Murillo, M.D., M.P.H., Suleeporn Sangrajrang, Ph.D., Rengaswamy Sankaranarayanan, M.D., Mona Saraiya, M.D., M.P.H., Mark Schiffman, M.D., M.P.H., Fanghui Zhao, M.D., Ph.D., Marc Arbyn, M.D., Ph.D., Walter Prendiville, F.R.C.O.G., Blanca I. Indave Ruiz, M.D., Ph.D., M.P.H., Isabel Mosquera-Metcalfe, Ph.D., and Béatrice Lauby-Secretan, Ph.D.
doi : 10.1056/NEJMsr2030640
N Engl J Med 2021; 385:1908-1918
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
doi : 10.1056/NEJMc2115204
N Engl J Med 2021; 385:1919-1920
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
doi : 10.1056/NEJMc2107661
N Engl J Med 2021; 385:e69
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
doi : 10.1056/NEJMc2113862
N Engl J Med 2021; 385:e70
SARS-CoV-2 Infection among Nursing Home Residents
doi : 10.1056/NEJMc2114113
N Engl J Med 2021; 385:e71
